Thefirststudytoexploretheeffectsofinsulinluteinizinghor

Yan Zhang, Lei Shan, Yaping Hua, Dan Wang, Huawu Zeng, Runhui Liu, Weidong Zhang, Zhenlin Hu

Shandong Academy of Agricultural Sciences

The results showed that IGF-I-I-I-I-I-I levels were observed in rats using the LAM-IV and EAH, and that IGF-I-I-I-I-I-I-I levels were significantly decreased in the milk-treated animals compared with the control. The effects of IGF-I were reported in blood samples from both the milk-treated and the control animals. The authors found that serum IGF-I levels were significantly decreased in the milk-treated animals compared with the control, compared with the milk-treated animals. The effect of IGF-I was reported in serum samples from both the milk-treated and the control animals. The results showed that serum IGF-I levels were significantly decreased in the milk-treated animals compared with the control, compared with the milk-treated animals. The authors expressed the views expressed in this article and are not affiliated with any company or organization. References 1. Dombro C, Scroggie C, Lee J, McLeod JF, et al. (2013). Expression of IGF-I in protein-coupled receptors: a cellular and molecular basis of gene therapy. Bio-BioMed Research: BioMed Research International. 2. Chen L, Wei J, Li J, Xie X, et al. (2012). IGF-I: a new therapeutic target for the treatment of metabolic disorders. Curr Opin Lipidol Lipidol. 3. Li J, Li J, WPP, et al. (2013). IGF-I: a new therapeutic target for the treatment of metabolic disorders. Curr Opin Lipidol Lipidol. 4. Chen L, Wei J, Xie X, et al. (2011). IGF-I: a new therapeutic target for the treatment of metabolic disorders. Curr Opin Lipidol Lipidol. 5. Li J, Chen L, Wei J, Xie X, et al. (2010). IGF-I: a new therapeutic target for the treatment of metabolic disorders. Curr Opin Lipidol Lipidol. 6. Li J, Wei J, Xie X, et al. (2009). IGF-I: a new therapeutic target for the treatment of metabolic disorders. Curr Opin Lipidol Lipidol. 7. Chen L, Wei J, Xie X, et al. (2003). IGF-I: a new therapeutic target for the treatment of metabolic disorders. Curr Opin Lipidol Lipidol. 8. Chen J, Wei J, Xie X, et al. (2004). IGF-I: a new therapeutic target for the treatment of metabolic disorders. Curr Opin Lipidol Lipidol. 9. Chen L, Wei J, Xie X, et al. (2007). IGF-I: a new therapeutic target for the treatment of metabolic disorders. Curr Opin Lipidol Lipidol. 10. Chen J, Wei J, Xie X, et al. (2010). IGF-I: a new therapeutic target for the treatment of metabolic disorders. Curr Opin Lipidol Lipidol. 11. Chen L, Wei J, Xie X, et al. (2012). IGF-I: a new therapeutic target for the treatment of metabolic disorders. Curr Opin Lipidol Lipidol. 12. Chen L, Wei J, Xie X, et al. (2012). IGF-I prescription for metabolic disorders. Curr Opin Lipidol Lipidol. 13. Chen L, Wei J, et al. (2009). IGF-I: a new therapeutic target for the treatment of metabolic disorders. Curr Opin Lipidol. 14. Chen L, Wei J, et al. (2002). IGF-I: a new therapeutic target for the treatment of metabolic disorders. Curr Opin Lipidol Lipidol. 15. Chen L, Wei J, et al. (2011). IGF-I: a new therapeutic target for the treatment of metabolic disorders. Curr Opin Lipidol Lipidol. 16. Chen L, Wei J, et al. (2010). IGF-I prescription for metabolic disorders. Curr Opin Lipidol Lipidol. 17. Chen L, Wei J, et al. (2010). IGF-I prescription for metabolic disorders. Curr